Absorbed Doses to Lungs and Cross-Fire Fraction
| Absorbed doses to the lungs (Gy) | |||||
| Treatment type | Evaluation | %DLungs←TL + NTL + RT* (%) | MIA (PM,Dmean) | MIA (PMCD,Dmean) | MIA (PMCD,DVHs) |
| WLI | E1 | 20 | 0.48 (0–3.5 × 101) | 0.58 (0–4.3 × 101) | 0.80 (0–5.9 × 101) |
| E2 | 22 | 0.54 (0–4.1 × 101) | 0.71 (0–5.4 × 101) | 0.91 (0–7.0 × 101) | |
| E3 | 14 | 0.71 (0–2.4 × 101) | 0.94 (0–3.1 × 101) | 1.05 (0–3.5 × 101) | |
| E4 | 4 | 3.32 (0–3.1 × 101) | 3.68 (0–3.4 × 101) | 7.14 (0–6.6 × 101) | |
| E5 | 100 | 0.14 (0–4.5 × 101) | 0.19 (0–6.1 × 101) | 0.24 (0–7.6 × 101) | |
| E6 | 100 | 0.08 (0–4.4 × 101) | 0.10 (0–5.2 × 101) | 0.13 (0–6.8 × 101) | |
| RLI | E7 | 100 | 0.31 (0–4.4 × 101) | 0.38 (0–5.4 × 101) | 0.43 (0–6.1 × 101) |
| E8 | 11 | 3.51 (0.6–5.3 × 101) | 4.04 (0.7–6.1 × 101) | 5.87 (1.0–8.9 × 101) | |
| E9 | 27 | 0.22 (0–1.9 × 101) | 0.29 (0–2.5 × 101) | 0.33 (0–2.8 × 101) | |
| E10 | 19 | 0.50 (0–3.6 × 101) | 0.64 (0–4.6 × 101) | 0.81 (0–5.8 × 101) | |
| LLI | E11 | 6 | 1.16 (0–6.2 × 101) | 1.92 (0–1.0 × 102) | 15.0 (0–8.0 × 102) |
| E12 | 4 | 2.20 (0–2.5 × 101) | 2.45 (0–2.8 × 101) | 7.14 (0–8.2 × 101) | |
| E13 | 3 | 1.57 (0–2.9 × 101) | 2.01 (0–3.8 × 101) | 8.03 (0–1.5 × 102) | |
| E14 | 48 | 0.19 (0–4.0 × 101) | 0.24 (0–5.1 × 101) | 1.60 (0–3.4 × 102) | |
| All types (n = 14) | Mean ± SD | 34 ± 38 | 1.07 ± 1.16 | 1.30 ± 1.31 | 3.53 ± 4.45 |
| WLI and RLI (n = 10) | Mean ± SD | 42 ± 41 | 0.98 ± 1.30 | 1.16 ± 1.45 | 1.77 ± 2.53 |
| LLI (n = 4) | Mean ± SD | 15 ± 22 | 1.28 ± 0.84 | 1.66 ± 0.97 | 7.94 ± 5.50 |
↵* Cross-fire contribution from NTL, TL, and RT fixations to the lungs.